secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001140361-23-053086
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GNI Group, Gyre's controlling shareholder, reports 9M 2023 revenue ¥20.5B (+61%), net profit ¥2.2B (+106%)
--------------------------------------------------------------------------------

- 9M 2023 revenue of ¥20,547.9M, up 61% from ¥12,761.0M in prior year.
- Net profit attributable to parent ¥2,213.3M vs ¥1,076.1M, more than doubled.
- Operating cash flow ¥4,443.0M, turning from negative ¥162.9M in prior year.
- Total assets ¥48,468.0M, up 33% from ¥36,456.9M at prior year-end.
- Basic EPS ¥46.61 (9M) vs ¥22.67; diluted EPS ¥46.13 vs ¥22.46.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123053086/0001140361-23-053086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123053086/ny20009756x17_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-053086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer